. 2019 May;81(2):233–239. doi: 10.18999/nagjms.81.2.233

Table 1.

Inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria
1. Unresectable locally advanced pancreatic cancer based on the resectability status of the NCCN guidelines 2. Age between 20 and 75 (at the time of informed consent) 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 4. No previous antitumor treatment 5. Within 10 × 10 cm radiation field for the primary lesion and regional lymph node 6. Adequate biliary drainage if obstructive jaundice is present 7. No direct invasion into the gastrointestinal tract 8. No simultaneous cancer in the other organs 9. Adequate oral intake 10. Expected more than 3 months survival 11. Adequate hematologic and major organ functions defined as; leukocyte count ≥ 3,500/mm³ and < 12,000/mm³, neutrophil count ≥ 2,000/mm³, hemoglobin level ≥ 9.0 g/dL, platelet count ≥ 100,000/mm³, total bilirubin level ≤ 2.0 mg/dL, aspartate aminotransferase and alanine aminotransferase levels ≤ 150 U/L, serum creatinine level ≤ 1.2 mg/dL, and creatinine clearance ≥ 50 mL/min 12. Written informed consent	1. Distant metastasis 2. History of severe drug hypersensitivity or allergy 3. Invasion into gastrointestinal tract 4. Obvious infection or inflammation 5. Serious medical or psychological condition interfere with treatment 6. Other concurrent or previous malignancy within the past 5 years, except a curative carcinoma in situ or mucosal cancer 7. Peripheral neuropathy > grade 2 8. Ascites or pleural effusion 9. Active gastrointestinal bleeding required blood transfusion 10. Diarrhea > grade 2 11. Obvious fibroid lung or interstitial pneumonia 12. Previous abdominal radiotherapy 13. Uncontrolled severe cancer pain 14. Radiation field included lung 15. Pregnancy, or women who desire to have children 16. Any reason why, in the opinions of the investigator, the patient should not participate

Inclusion criteria

Exclusion criteria

1. Unresectable locally advanced pancreatic cancer based on the resectability status of the NCCN guidelines
2. Age between 20 and 75 (at the time of informed consent)
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
4. No previous antitumor treatment
5. Within 10 × 10 cm radiation field for the primary lesion and regional lymph node
6. Adequate biliary drainage if obstructive jaundice is present
7. No direct invasion into the gastrointestinal tract
8. No simultaneous cancer in the other organs
9. Adequate oral intake
10. Expected more than 3 months survival
11. Adequate hematologic and major organ functions defined as;
leukocyte count ≥ 3,500/mm³ and < 12,000/mm³, neutrophil count ≥ 2,000/mm³, hemoglobin level ≥ 9.0 g/dL, platelet count ≥ 100,000/mm³, total bilirubin level ≤ 2.0 mg/dL, aspartate aminotransferase and alanine aminotransferase levels ≤ 150 U/L, serum creatinine level ≤ 1.2 mg/dL, and creatinine clearance ≥ 50 mL/min
12. Written informed consent

1. Distant metastasis
2. History of severe drug hypersensitivity or allergy
3. Invasion into gastrointestinal tract
4. Obvious infection or inflammation
5. Serious medical or psychological condition interfere with treatment
6. Other concurrent or previous malignancy within the past 5 years, except a curative carcinoma in situ or mucosal cancer
7. Peripheral neuropathy > grade 2
8. Ascites or pleural effusion
9. Active gastrointestinal bleeding required blood transfusion
10. Diarrhea > grade 2
11. Obvious fibroid lung or interstitial pneumonia
12. Previous abdominal radiotherapy
13. Uncontrolled severe cancer pain
14. Radiation field included lung
15. Pregnancy, or women who desire to have children
16. Any reason why, in the opinions of the investigator, the patient should not participate